{"id":"W4385667045","doi":"10.1097/01.hs9.0000970976.05785.80","title":"P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Discontinuation; Oncology; Gastroenterology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002076688,0.0003106699,0.0006380856,0.0001407904,0.00007307336,0.00002181033,0.000093148,0.0001594986,0.001341702],"category_scores_gemma":[0.0003987386,0.0002590909,0.0000819847,0.0006220039,0.00005586464,0.00005050781,0.0001001207,0.0001956118,0.0008774286],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001039226,"about_ca_system_score_gemma":0.000100297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008806901,"about_ca_topic_score_gemma":0.0005457924,"domain_scores_codex":[0.9978061,0.00008557503,0.0006409723,0.0006638195,0.0003987773,0.0004047286],"domain_scores_gemma":[0.9982961,0.000666688,0.000126644,0.0005055504,0.00009637475,0.0003086767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09214003,0.01298328,0.4362628,0.001122469,0.00245886,0.005851567,0.02402718,0.0008754095,0.02985512,0.0189704,0.2567039,0.1187489],"study_design_scores_gemma":[0.01669529,0.002447636,0.9211441,0.001530769,0.000132899,0.00002433106,0.001053487,0.00009833608,0.0344365,0.0002493192,0.0218345,0.0003527833],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9724218,0.0001503626,0.000001464368,0.003284284,0.00009476075,0.001047935,0.0005708773,0.0001125439,0.02231593],"genre_scores_gemma":[0.9948582,0.0002882098,0.000679818,0.0006055505,0.0001247936,0.00008576267,0.0007625229,0.00004812712,0.002546988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4848813,"threshold_uncertainty_score":0.9999861,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02406813518054925,"score_gpt":0.296001022558554,"score_spread":0.2719328873780048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}